Current intravesical therapy for non-muscle invasive bladder cancer

Expert Opinion on Biological Therapy

Volumn 13, Issue 10, 2013, Pages 1371-1385

  Van Lingen, Anna V ^a   Witjes, J Alfred ^a  

^a RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Bacillus Calmette Gu rin; Intravesical therapy; Non muscle invasive bladder carcinoma; Photo dynamic diagnosis; Risk assessment; Single post operative instillation; Transurethral resection of bladder tumour; Urothelial carcinoma

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; AMINOLEVULINIC ACID; ANTINEOPLASTIC AGENT; APAZIQUONE; BCG VACCINE; CG 0070; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMIQUIMOD; IMMUNOMODULATING AGENT; ISONIAZID; KEYHOLE LIMPET HEMOCYANIN; MITOMYCIN; OFLOXACIN; ONCOLYTIC ADENOVIRUS; OPORTUZUMAB MONATOX; PACLITAXEL; SCH 721015; TMX 101; UNCLASSIFIED DRUG; VALRUBICIN;

ADJUVANT THERAPY; ANTIBIOTIC PROPHYLAXIS; ANTINEOPLASTIC ACTIVITY; BACTERIAL STRAIN; BLADDER CARCINOMA; BLADDER METASTASIS; BLADDER OBSTRUCTION; BONE MARROW SUPPRESSION; CALCIFICATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CONTACT DERMATITIS; CYSTECTOMY; CYSTITIS; CYSTOSCOPY; DISEASE FREE SURVIVAL; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INSTILLATION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FLUORESCENCE IMAGING; GRANULOMATOSIS; HEMATURIA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYPERTHERMIC THERAPY; INTRAVESICAL DRUG ADMINISTRATION; LOW RISK POPULATION; MAINTENANCE CHEMOTHERAPY; NARROW BAND IMAGING; NON MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; OPTIMAL DRUG DOSE; ORCHITIS; OVERALL SURVIVAL; PHOTODYNAMIC THERAPY; PROGRESSION FREE SURVIVAL; PROSTATITIS; RADICAL RESECTION; RECURRENCE FREE SURVIVAL; REOPERATION; REVIEW; RISK ASSESSMENT; STRAIN DIFFERENCE; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF THE BLADDER TUMOR; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URETER OBSTRUCTION; WHITE LIGHT ENDOSCOPY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRAVESICAL; BCG VACCINE; HUMANS; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 84884240429     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2013.824421     Document Type: Review

References (117)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute, Bethesda, Md, USA; 2011. Available from: Http://seer.cancer. gov/csr/1975-2008/
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60(5):277-300
3. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2012. CA Cancer J Clin 2012;62(1):10-29
4. Parkin DM. The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl2008;218):12-20
5. McDougal W.S, Wein A.J, Kavoussi L.R, et al. Campbell-Walsh Urology. 10th edition. Saunders Elsevier. Review Philadelphia: 2011
6. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61(2):69-90
7. Heijden AG Vd Witjes JA. Recurrence, progression, and follow-up in non-muscle-invasive bladder cancer. Eur Urol Suppl2009;8(7):556-62
8. van Rhijn BW, Burger M, Lotan Y, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: From epidemiology to treatment strategy. Eur Urol 2009;56(3):430-42
9. Hall MC, Chang SS, Dalbagni G, et al. AUA Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007;178(6):2314-30
10. Williams SK, Hoenig DM, Ghavamian R, Soloway M. Intravesical therapy for bladder cancer. Expert Opin Pharmacother 2010;11(6):947-58
11. Divrik RT, Sahin AF, Yildirim U, et al. Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: A prospective randomised clinical trial. Eur Urol 2010;58(2):185-90
12. Dutta SC, Smith JA Jr., Shappell SB, et al. Clinical under staging of high risk nonmuscle invasive urothelial carcinomatreated with radical cystectomy. J Urol 2001;166(2):490-3
13. Brausi M, Collette L, Kurth K, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: A combined analysis of seven EORTC studies. Eur Urol 2002;41(5):523-31
14. Brausi MA, Gavioli M, Peracchia G, et al. Dedicated teaching programs can improve the quality of TUR of non-muscle-invasive bladder tumors (NMIBT): Experience of a single institution [abstract 1794]. J Urol 2008;179:4-615
15. Mariappan P, Zachou A, Grigor KM. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience. Eur Urol 2010;57(5):843-9
16. Mariappan P, Finney SM, Head E, et al. Good quality white-light transurethral resection of bladder tumours (GQWLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: Validation across time and place and recommendation for benchmarking. BJU Int 2012;109(11):1666-73
17. Zaak D, Kriegmair M, Stepp H, et al. Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: Results of 1012 fluorescence endoscopies. Urology 2001;57(4):690-4
18. Riedl CR, Daniltchenko D, Koenig F, et al. Fluorescence endoscopy with 5-aminolevulinic acid reduces early recurrence rate in superficial bladder cancer. J Urol 2001;165(4):1121-3
19. Kriegmair M, Zaak D, Rothenberger KH, et al. Transurethral resection for bladder cancer using 5-aminolevulinic acid induced fluorescence endoscopy versus white light endoscopy. J Urol 2002;168(2):475-8
20. Filbeck T, Pichlmeier U, Knuechel R, et al. Clinically relevant improvement of recurrence-free survival with 5-aminolevulinic acid induced fluorescence diagnosis in patients with superficial bladder tumors. J Urol 2002;168(1):67-71
21. Schumacher MC, Holmäng S, Davidsson T, et al. Transurethral resection of non-muscle-invasive bladder transitional cell cancers with or without 5-aminolevulinic Acid under visible and fluorescent light: Results of a prospective, randomised, multicentre study. Eur Urol 2010;57(2):293-9
22. Grossman HB, Stenzl A, Fradet Y, et al. Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 2012;188(1):58-62
23. Draga RO, Grimbergen MC, Kok ET, et al. Photodynamic diagnosis (5 aminolevulinic acid) of transitional cell carcinoma after bacillus Calmette-Guérin immunotherapy and mitomycin C intravesical therapy. Eur Urol 2010;57(4):655-60
24. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011;59(6):997-1008
25. Witjes JA, Redorta JP, Jacqmin D, et al. Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: Review of the evidence and recommendations. Eur Urol 2010;57(4):607-14
26. Hermann GG, Mogensen K, Toft BG, et al. Outpatient diagnostic of bladder tumours in flexible cystoscopes: Evaluation of fluorescence-guided flexible cystoscopy and bladder biopsies. Scand J Urol Nephrol 2012;46(1):31-6
27. Cauberg EC, Mamoulakis C, de la Rosette JJ, de Reijke TM. Narrow band imaging-assisted transurethral resection for non-muscle invasive bladder cancer significantly reduces residual tumour rate. World J Urol 2011;29(4):503-9
28. Schmidbauer J, Remzi M, Klatte T, et al. Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol 2009;56(6):914-19
29. Wiesner C, Jäger W, Salzer A, et al. Confocal laser endomicroscopy for the diagnosis of urothelial bladder neoplasia: A technology of the futurëBJU Int 2011;107(3):399-403
30. Miladi M, Peyromaure M, Zerbib M, et al. The value of a second transurethral resection in evaluating patients with bladder tumours. Eur Urol 2003;43(3):241-5
31. Kulkarni GS, Hakenberg OW, Gschwend JE, et al. An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 2010;57(1):60-70
32. Jakse G, Algaba F, Malmström P-U, Oosterlinck W. A second-look TUR in T1 transitional cell carcinoma: WhÿEur Urol 2004;45:539-46
33. Edge SB, Byrd DR, Compton CC. editors. et al. AJCC Cancer staging manual. 7th edition. Springer-Verlag; New York: 2009
34. Lamm DL, van der Meijden APM, Morales A, et al. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147:596-600
35. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/ International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol 1998;22(12):1435-48
36. Sauter G, Algaba F, Amin M, et al. Tumours of the urinary system: Non-invasive urothelial neoplasias. In: Eble JN, Sauter G, Epstein Jl, Sesterhenn I, editors. WHO classification of classification of tumours of the urinary system and male genital organs. Lyon: IARCC Press; 2004. p. 29-34
37. Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int 2011;107(3):404-8
38. Cao D, Vollmer RT, Luly J, et al. Comparison of 2004 and 1973 World Health Organization grading systems and their relationship to pathologic staging for predicting long-term prognosis in patients with urothelial carcinoma. Urology 2010;76(3):593-9
39. Pellucchi F, Freschi M, Ibrahim B, et al. Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. J Urol 2011;186(6):2194-9
40. May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: A multicentre study comparing the 1973 and 2004 World Health Organisation Classifications. Eur Urol 2010;57(5):850-8
41. Sylvester RJ, van der Meijden AP, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage TaT1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-5
42. Brausi M, Witjes JA, Lamm D, et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186(6):2158-67
43. Tanaka N, Kikuchi E, Matsumoto K, et al. Frequency of tumor recurrence: A strong predictor of stage progression in initially diagnosed nonmuscle invasive bladder cancer. J Urol 2011;185(2):450-5
44. Fernandez-Gomez J, Madero R, Solsona E, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model. J Urol 2009;182(5):2195-203
45. Fernandez-Gomez J, Madero R, Solsona E, et al. Club Urológico Español de Tratamiento Oncológico. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: External validation of the EORTC risk tables. Eur Urol 2011;60(3):423-30
46. Babjuk M, Burger M, Zigeuner R, et al. Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS). 2013. Available from: Http://www. uroweb.org/fileadmin/guidelines/ Total-file;2013-large;guidelines; prints.pdf
47. van Rhijn BW, Liu L, Vis AN, et al. Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. BJU Int 2012;110(8):1169-76 gender as a risk factor and discussing several markers and their added value
48. Rouprêt M, Seisen T, Compérat E, et al. (Comité de Cancérologie de l'Association Française d'Urologie). Prognostic Interest in Discriminating Muscularis Mucosa Invasion (T1a vs T1b) in Nonmuscle Invasive Bladder Carcinoma: Results of a French National Multicenter Study with Central Pathology Review. J Urol 2012;doi:pii: S0022-5347(12)05631-5. 10.1016/j. juro.2012.11.120
49. Brimo F, Wu C, Zeizafoun N, et al. Prognostic factors in T1 bladder urothelial carcinoma: The value of recording millimetric depth of invasion, diameter of invasive carcinoma, and muscularis mucosa invasion. Hum Pathol 2013;44(1):95-102
50. van Rhijn BW, van der Kwast TH, Alkhateeb SS, et al. A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 2012;61(2):378-84
51. Palou J, Sylvester RJ, Faba OR, et al. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence. progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62(1):118-25
52. Kluth LA, Fajkovic H, Xylinas E, et al. Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2012; [Epub ahead of print]
53. Noon AP, Albertsen PC, Thoams F, et al. Competing mortality in patients diagnosed with bladder cancer: Evidence of undertreatment in the elderly and female patients. BJC 2013;108:1534-40
54. Lamm D, Colombel M, Persad R, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol 2008;7:651-66
55. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 2004;171(6 PT1):2186-90
56. Gudjónsson S, Adell L, Merdasa F, et al. Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection̈The results of a prospective randomised multicentre study. Eur Urol 2009;55(4):773-80
57. Berrum-Svennung I, Granfors T, Jahnson S, et al. A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 2008;179(1):101-5; discussion 105-6
58. Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int 2001;88(3):209-16
59. Nieder AM, Brausi M, Lamm D, et al. Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 2005;66(6):108-25
60. Muto S, Nakajima A, Horiuchi A, et al. Maintenance therapy with intravesical bacillus Calmette-Guerin in patients with intermediate- or high-risk non-muscle-invasive bladder cancer. J Clin Oncol 2013;43(3):305-13
61. Böhle A, Jocham D, Bock PR. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003;169(1):90-5
62. Malmström PU, Sylvester RJ, Crawford DE, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56(2):247-56
63. Shelley MD, Wilt TJ, Court J, et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU Int 2004;93(4):485-90
64. Sylvester RJ, Brausi MA, Kirkels WJ, et al. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediateand high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57(5):766-73
65. Han RF, Pan JG. Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer̈A meta-analysis of randomized trials. Urology 2006;67(6):1216-23
66. Shelley MD, Court JB, Kynaston H, et al. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003(3):CD003231
67. Vázquez-Lavista LG, Flores-Balcázar CH, Llorente L. The bacillus Calmette-Guérin as immunomodulator in bladder cancer. Rev Invest Clin 2007;59(2):146-52
68. Böhle A, Brandau S. Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 2003;170(3):964-9
69. Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: A meta-analysis of the published results of randomized clinical trials. J Urol 2002;168(5):1964-70
70. Vegt PD, Witjes JA, Witjes WP, et al. A randomized study of intrasvesical Mitomycin-C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol 1995;153:929-33
71. Secanella-Fandos S, Luquin M, Julián E. Connaught and Russian strains showed the highest direct antitumor effects of different bacillus calmette-guérin substrains. J Urol 2013;189(2):711-18
72. Birkhaeuser FD, Rentsch CA, Studer UE, et al. 1672: A randomized Phase III study comparing Immucyst; versus Oncotice;: The BCG strain used makes a difference! Abstract podium session, Bladder Cancer: Superficial I, AUA congress. 2012. Available from: Http://www.aua2012.org/abstracts/ printpdf.cfm?ID=1672
73. Witjes JA, Palou J, Soloway M, et al. Clinical practice recommendations for the prevention and management of intravesical therapy-associated adverse events. Eur Urol Suppl2008;7(10):667-74
74. Colombel M, Saint F, Chopin D, et al. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: Results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol 2006;176:935-9
75. Pansadoro V, Emiliozzi P, de Paula F, et al. Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002;59:227-31
76. Van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. EORTC Genito-Urinary Tract Cancer Group. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44(4):429-34
77. Martinez-Pineiro JA, Flores N, Isorna S, et al. CUETO (Club Urologico Espanol de Tratamiento Oncologico). Longterm follow-up of a randomized prospective trial comparing a standard 81 mgdose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002;89:671-80
78. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. CUETO (Club Urologico Espanol de Tratamiento Oncologico). Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dosëResults of a prospective randomized trial. J Urol 2005;174:1242-7
79. Ojea A, Nogueira JL, Solsona E, et al. Members of the CUETO Group (Club Uroló gico Espan̈ol De Tratamiento Oncologico). A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: Low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol 2007;52:1398-406
80. Oddens J, Brausi M, Sylvester R, et al. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63(3):462-72 treatment
81. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapÿAre six weekly instillations necessarÿEur Urol 2000;37(4):470-7
82. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study. J Urol 2000;163(4):1124-9
83. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 1976;116(2):180-3
84. Yates DR, Brausi MA, Catto JWF, et al. Treatment options available for Bacilus Calmette-Guerin Failure in non-muscle invasive bladder cancer. Eur Urol 2012;62:1088-96
85. De Reijke TM, Kurth KH, Sylvester RJ, et al. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: Results of a European Organization for the Research and Treatment of Cancer Genito-Urinary Group phase III trial (30906). J Urol 2005;173:405-9
86. Witjes JA. Management of BCG failures in superficial bladder cancer: A review. Eur Urol 2006;49:790-7
87. Losa A, Hurle R, Lembo A. Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: Long-term results. J Urol 2000;163:68-72
88. Jakse G, Hall R, Bono A, et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: Long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 2001;40:144-50
89. Schrier BPH, Hollander MP, van Rhijn BWG, et al. Prognosis of muscle-invasive bladder cancer: Difference between primary and progressive tumours and implications for therapy. Eur Urol 2004;45:292-6
90. van den Bosch S, Witjes JA. Long-term cancer-specific survival in patients with high-risk, non-muscle-invasive bladder cancer and tumour progression: A systematic review. Eur Urol 2011;60(3):493-500
91. Kakiashvili DM, van Rhijn BW, Trottier G, et al. Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille. Calmette-Guérin treatment. BJU Int 2011;107(4):540-6
92. Oosterlinck W, Kirkali Z, Sylvester R, et al. Sequential intravesical chemoimmunotherapy with mitomycin C and bacillus Calmette-Guérin and with bacillus Calmette-Guérin alone in patients with carcinoma in situ of the urinary bladder: Results of an EORTC genito-urinary group randomized phase 2 trial (30993). Eur Urol 2011;59(3):438-46
93. Zuiverloon TCM, Nieuweboer AJM, Vékony H, et al. Markers predicting response to BCG immunotherapy in high-risk bladder cancer patients: A systematic review. Eur Urol 2012;61:128-45
94. Agundez M, Grau L, Palou J, et al. Evaluation of the methylation status of tumour suppressor genes for predicting bacillus Calmette-Guérin response in patients with T1G3 high-risk bladder tumours. Eur Urol 2011;60(1):131-40
95. Shelley MD, Jones G, Cleves A, et al. Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): A systematic review. BJU Int 2012;109(4):496-505
96. O'Donnell MA, Lilli K, Leopold C; National Bacillus Calmette-Guerin/ Interferon Phase 2 Investigator Group. Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer. J Urol 2004;172:888-93
97. Joudi FN, Smith BJ, O'Donnell MA; National BCG-Interferon Phase II Investigator Group. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 2006;24:344-8
98. Witjes JA, Hendricksen K, Gofrit O, et al. Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: Experience of the European Synergo; working party. World J Urol 2009;27(3):319-24
99. van der Heijden AG, Kiemeney LA, Gofrit ON, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46(1):65-71
100. Nativ O, Witjes JA, Hendricksen K, et al. Combined thermo-chemotherapy for recurrent bladder cancer after bacillus Calmette-Guerin. J Urol 2009;182(4):1313-17
101. Burke JM, Lamm DL, Meng MV, et al. A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer. J Urol 2012;188(6):2391-7
102. Morales A, Phadke K, Steinhoff G. Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed. J Urol 2009;181(3):1040-5
103. Comprehensive Cancer Network National. Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 2, 2011
104. Steinberg G, Bahnson R, Brosman S, et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000;163(3):761
105. Laudano MA, Barlow LJ, Murphy AM, et al. Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy. Urology 2010;75(1):134-7
106. Barlow L, McKiernan J, Sawczuk I, Benson M. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy. BJU Int 2009;104(8):1098-102
107. Barlow L, McKiernan JM, Benson MC. Long-term survival outcomes with intravesical docetaxel for recurrent nonmuscle invasive bladder cancer after previous bacillus Calmette-Guérin therapy. J Urol 2013;189(3):834-9
108. Zlotta AR, Fleshner NE, Jewett MA. The management of BCG failure in non-muscle-invasive bladder cancer: An update. Can Urol Assoc J 2009;3(6 Suppl4):S199-205
109. Lammers RJ, Witjes WP, Janzing-Pastors MH, et al. Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: Results from a prospective randomized phase III trial. J Clin Oncol 2012;30(18):2273-9
110. Falke J, Lammers RJ, Arentsen HC, et al. Results of a phase 1 dose escalation study of intravesical TMX-101 in patients with non-muscle invasive bladder cancer. J Urol 2012;S0022-5347(12):05771-0
111. Barocas DA, Globe DR, Colayco DC, et al. Surveillance and Treatment of Non-Muscle-Invasive Bladder Cancer in the USA. Advances in Urology 2012;421709:1-8; doi: 10.1155/2012/ 421709
112. van der Heijden AG, Moonen PMJ, Cornel EB, et al. Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: Toxicity and marker response. J Urol 2006;176(4):1349-53
113. Hendricksen K, Cornel EB, de Reijke TM, et al. Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol 2012;187(4):1195-9
114. Di Stasi SM, Giannantoni A, Giurioli A, et al. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial. Lancet Oncol 2006;7:43-51
115. Di Stasi SM, Valenti M, Verri C, et al. Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: A randomised controlled trial. Lancet Oncol 2011;12:871-9
116. Colombo R, Lev A, Da Pozzo LF, et al. A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment. J Urol 1995;153:959-63
117. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review. Eur Urol 2011;60:81-93